BiotechTube

Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Crohn Disease

Conditions

Crohn Disease

Trial Timeline

Dec 21, 2021 → Jun 15, 2024

NCT ID
NCT05072782

About Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)

Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate) is a approved stage product being developed by Celltrion for Crohn Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT05072782. Target conditions include Crohn Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05072782ApprovedUNKNOWN

Competing Products

20 competing products in Crohn Disease

See all competitors
ProductCompanyStageHype Score
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
47
LY4395089 + Mirikizumab - Intravenous (IV) + Mirikizumab - Subcutaneous (SC)Eli LillyPhase 2
52
CT-P13 + RemicadeCelltrionPhase 3
77
Ustekinumab 45 mg + Ustekinumab 90 mgCelltrionPre-clinical
23
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
33
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
CP-461Astellas PharmaPhase 2
52
UstekinumabSun PharmaceuticalPre-clinical
23
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
41
E6011 + PlaceboEisaiPhase 2
52
E6011 + PlaceboEisaiPhase 1
33
adalimumab + adalimumab + placeboEisaiPhase 2/3
65
adalimumabEisaiPhase 2/3
65
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
77
MirikizumabEli LillyPhase 3
77
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
77
Mirikizumab + PlaceboEli LillyPhase 2
52
MirikizumabEli LillyPhase 3
77

Other Products from Celltrion

Azathioprine + PlaceboApproved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85
CT-P39 + EU-approved XolairPhase 3
77